A Leuconostoc mesenteroides ssp. mesenteroides was isolated from goat's milk on the basis of its ability to inhibit the growth of Listeria monocytogenes. The antimicrobial effect was due to the presence in the culture medium of a compound, named mesentericin Y 105, excreted by the Leuconostoc mesenteroides Y 105. The compound displayed known features of bacteriocins from lactic acid bacteria. It appeared as a proteinaceous molecule exhibiting a narrow inhibitory spectrum limited to genus Listeria, The apparent relative molecular mass, as indicated by activity detection after SDS-PAGE, was 2-5-3-0 kDa. The bacteriocin was purified to homogeneity by a simple three-step procedure: a crude supernatant obtained from an early-stationary-phase culture in a defined medium was subjected to affinity chromatography on a blue agarose column, followed by ultrafiltration through a 5 kDa cut-off membrane, and finally by reverse-phase HPLC on a C4 column. Microsequencing of the pure bacteriocin and of tryptic fragments showed that mesentericin Y 105 is a 36 amino acid polypeptide whose primary structure is close to that of leucocin A-UAL 187, which contains an extra residue at the C-terminus and displays only two differences in the overlapping sequence. However, unlike leucocin A-UAL 187, mesentericin Y 105 displayed a bactericidal mode of action.
Introduction
Antimicrobial activities of lactic acid bacteria have been widely investigated in the past 10 years (Daeschel, 1989; Piard & Desmazeaud, 199 1) . Whereas broad-spectrum inhibition is generally attributed to organic acid production and/or to hydrogen peroxide, a narrow inhibitory spectrum, that includes mainly homologous strains, is displayed by some species. The latter effect is linked to the synthesis and the secretion of bacteriocins, i.e. molecules of proteinaceous nature, whose bactericidal or bacteriostatic activity is directed towards a limited number of bacterial species (Tagg et al., 1976; Klaenhammer, 1988) . Increasing efforts have therefore been made to seek a large array of bacteriocin-producing strains and to characterize the bacteriocins as well as the target cells. Several food-contaminating bacteria were identified as pathogens responsible for human diseases. The growing number of animal and human cases of listeriosis (Farber & Peterkin, 1991) due to the presence of Listeria monocytogenes in meat (Johnson et al., 1990) and the fact that they are closely related to Lactobacilluceae led to the identification of anti-Listeria lactic acid bacteria.
Some antagonistic lactic acid bacteria strains delaying Listeria growth were identified (Harris et al., 1989; Stiles & Hastings, 199 1) including one Leuconostoc mesenteroides and two Leuconostoc gelidurn (Harding & Shaw, 1990; Daba et al., 1991; . Bacteriocin purification was in some cases achieved, but only a few primary structures were directly determined or deduced from their gene sequence, e.g. lactacin F (Muriana & Klaenhammer, 1991) , helveticin J (Joerger & Klaenhammer, 1990) , lactocin S (Mortvedt et al., 1991) , lactococcin A and recently leucocin A-UAL 187 . Among those well-characterized bacteriocins, only leucocin A-UAL 187 appears inhibitory to Listeria monocytogenes. The bacteriocin family seems largely heterologous, since its members fall into a wide molecular mass range (from Y . Hdchard and others 2.5 kDa to approx. 60 kDa) as estimated by SDS-PAGE. The nature of the genetic determinants for bacteriocins, in spite of noticeable exceptions, e.g. helveticin J which is chromosomally produced (Joerger & Klaenhammer, 1986) , are plasmid linked. Plasmid-encoded immunity is also displayed by the bacteriocin-producing strains (Klaenhammer, 1988) . Since microbially-produced compounds such as nisin can be declared safe for humans, further characterization of anti-listeria bacteriocins is of great interest to the food industry.
In this report, a new bacteriocin-producing Leuconostoc rnesenteroides strain Y 105 isolated from goat's milk is described. The bacteriocin, named mesentericin Y 105, appeared mainly inhibitory to Listeria monocytogenes. A crude preparation was first submitted to various chemical and physical treatments, then purified and sequenced.
Methods
Bacterial strains and media. Lactic acid bacteria were isolated from goat's milk. They were propagated (1 %, v/v, inoculum) aerobically in lactobacilli MRS or MI7 broth (Biokar, France) at 30 "C, and then tested for their ability to inhibit the growth of an indicator strain, namely Listeria monocytogenes E20. as previously described (Hechard et al., 1990) . Listeria monocytogenes E20 (serotype 4), a strain of hospital origin, was grown aerobically in Tryptic Soy Broth (Difco) at 30 "C for 16-20 h before use in the antagonism assay.
Preparation of bacteriocin extracts. The bacteriocin-producing strain was grown to the stationary phase by incubating at 30 "C for 16 h in MRS or 24 h in a defined medium; 52.5 gl-I Methionine Assay Medium (Difco), 100 mg 1 -I DL-methionhe. The final pH of the culture was 4.2 (MRS) to 5.0 (defined medium). Crude extracts were prepared as follows. The culture was either used directly or adjusted to pH 6.8 with NaOH. The bacteria were then removed by centrifugation (6000g, 10 min) and the supernatant was passed through a 0.22 pm Millex-GV filter (Millipore). A concentrated extract, used for SDS-PAGE, was obtained by adding ammonium sulphate to the crude extract to a concentration of 60% (w/v). After incubation for 2 h at 4 "C the precipitate was collected and dialysed using a membrane with a cutoff of 6000-8000 Da (Spectrum), against 10 mM-sodium phosphate buffer (pH 6.8).
Bacteriocin detection. Bacteriocin was detected by an antagonism well-diffusion method, inoculating 1 % of the indicator strain L. monocytogenes E20 culture in Tryptic Soy buffered agar (pH 7.3) to avoid acid inhibition: 30 g I-' Tryptic Soy Broth; 1.5 g I-' KH,P04; 3.5 g I-' Na,HPO,; 15 g 1-' agar (Hechard et al., 1990) . Wells were punched in the agar plate and filled with 100 p1 of test samples. After overnight incubation at 30 "C, zones of inhibition were examined and their radii were measured.
Activity assay and spectrum. Mesentericin Y 105 activity was estimated by the critical dilution method. Serial two-fold dilutions of bacteriocin extracts were tested by the well-diffusion method described above. The titre, expressed in activity units per millilitre (AU ml-'), was defined as the reciprocal of the highest dilution showing a radius of inhibition zone greater than 1 mm.
The well-diffusion method was used to examine the antimicrobial activity of crude mesentericin Y I05 extracts towards several Gramnegative or Gram-positive bacteria, such as food-spoilage and lactic acid organisms from the collection of the Institut Universitaire de Technologie (La Rochelle, France) or Listeria strains kindly provided by P. Cossart (Laboratoire de Genetique Moliculaire des Listeria, Institut Pasteur, Paris, France). These strains were subcultured in the appropriate medium and then inoculated in the agar medium.
Protease, heat and storage stability. Crude extracts of mesentericin Y105, at the pH of the culture or adjusted to pH 6.8, were independently submitted to either (i) 2 h in the presence of different proteases (1 mg ml-I): pronase, proteinase K, trypsin, chymotrypsin and pepsin purchased from Boehringer Mannheim, (ii) heating for 30, 60 and 120 min at 60 "C and 100 "C and sterilization for 30 min at 121 "C, or (iii) storage at -2O"C, +4"C and at room temperature, with or without a 30 min pre-treatment at 95 "C. The biological activity of the different samples was then determined by the activity assay.
PuriJication of mesentericin Y105. A crude extract obtained after culturing in defined medium (540 ml, pH 5.0) was loaded onto an affinity chromatography column (30 ml of 1 pm ml-l Blue Agarose, Kem-En-Consult, Hellerup, Denmark). The column was first washed with 20 mwacetate buffer, pH 5-0, to remove unbound proteins. Mesentericin Y105 was then eluted with 1 M-NaCI in the same buffer. Fractions were collected and tested by the well-diffusion method. Those displaying bacteriocin activity were assembled and concentrated in a Minitan ultrafiltration system (Millipore) with a 5 kDa cut-off membrane. The retentate was dialysed against water to remove the salts, and finally evaporated in a Speed-vac concentrator. The bacteriocin was further purified by reverse-phase HPLC on a 25 cm Nucleosil 300A C4 column (Colochrom), using a 6 to 60% (v/v) acetonitrile gradient. Buffers were as follows: (A) 0.1 % trifluoroacetic acid (TFA), (B) 60% (v/v) acetonitrile in 0.1% TFA. Elution of proteins was performed by running a 60 min gradient from 90% A/10% B to 100% B (0.8 ml min-I). Fractions were tested for anti-Listeria activity, and then evaporated in a Speed-vac concentrator. A part of the sample was kept for direct sequencing while the rest was subjected to trypsin digestion.
Trypsin digestion. About 1 1 pg of pure mesentericin Y I05 was treated with 0.4pg trypsin TPCK (Sigma) in 2 0 0~1 0.1 M-ammonium bicarbonate buffer at pH 7.8. After 10 h at 37 "C, the sample was directly applied to a reverse-phase HPLC C4 column as described above for intact mesentericin. Individual tryptic fragments were collected, evaporated and sequenced.
Amino acid sequence determination. The amino-terminal sequence analysis of the protein and of the tryptic peptides was performed by L. Denoroy at the Service Central d'Analyse, Centre National de la Recherche Scientifique, Vernaison, France.
SDS-PAGE.
The apparent molecular mass of mesentericin Y I05 was estimated by Tricine-SDS-PAGE, done on 0.75 mm gels as described by Schagger & Von Jagow (1987) . Concentrating and separating gels were separated by a spacer gel. The polyacrylamide concentration of the 3 gels was 4, 16.5 and 10% (w/v), respectively. The separating gel contained 10% (v/v) glycerol. Migration was performed in a vertical slab gel apparatus (Mighty small, Hoeffer Instruments), at a constant voltage (1 50 V) for approximately 2 h. Part of the gel was silver-stained (Giulian et al., 1983) while the other was assayed for antimicrobial activity by direct test as previously described (Bhunia et a/., 1987).
Results

Isolation of bacteriocin producing strains
Out of 120 goat's milk samples screened, 64 lactic acid bacteria were isolated on the basis of Gram stain, catalase and oxidase tests. They were screened for their Germany) , showed that the bacteriocin-producing strain was a Leuconostoc mesenteroides ssp. mesenteroides named Y 105. Therefore the bacteriocin was termed mesentericin Y 105. The growth of Leuconostoc mesenteroides Y 105 was followed for 24 h at 30 "C in MRS medium. An increase in the antagonism activity of the culture supernatant (i.e. bacteriocin excretion) occurred continuously after a lag period of 3 h, until the late exponential phase, and production of the mesentericin Y105 was higher at 30 "C than at 37 "C (data not shown).
Inhibitory spectrum
The inhibitory spectrum of mesentericin Y 105 was assessed by testing its efficiency toward various Gramnegative and Gram-positive bacteria, including other lactic acid bacteria and several pathogenic strains. Table  1 shows that the bacteriocin produced is specific for Listeria genus. All of the Listeria strains were inhibited when tested by the well-diffusion test. Some Listeria ivanovii ssp. were highly sensitive to the bacteriocin as compared with our reference strain ( L . monocytogenes E20). On the other hand, Listeria murrayi BUG 503 displayed a minimal response. Neither the Gramnegative and other Gram-positive indicator bacteria, nor the related lactic acid bacteria species were inhibited within the limits of detection of the assay. Therefore it was concluded that the producer strain had a narrow inhibitory spectrum limited to Listeria.
Properties of mesentericin Y10.5
Crude mesentericin Y 105 extract was adjusted to pH 4.5 or 6-8 and submitted to various conditions: protease treatment, heat ( Fig. 1 ) and storage at different pH and temperatures. The activity was then measured by the well-diffusion test. All of the proteolytic enzymes tested (pronase, proteinase K, trypsin, chymotrypsin and pepsin; 1 mg ml-l) totally inhibited the activity after 2 h treatment, except the sample of crude extract (pH 6.8) treated with pepsin, which remained active, probably because this protease is normally inhibited at pH > 6 (Fig. 1) . The bacteriocin remained active after 120 min at 60 "C (320 AU ml-l). Higher temperature treatment showed that mesentericin Y 105 was more stable under initial conditions at pH 4.5 than in a medium adjusted to pH 6-8. Samples at pH 4.5 had to be autoclaved or treated at 100 "C for 120 min to lose part of their activity (80 AU ml-l), whereas activity of samples at pH 6.8 2,30 min at 60 "C; 3,60 min at 60 "C; 4,120 rnin at 60 "C; 5,30 min at 100 "C; 6,60 min at 100°C; 7, 120 min at 100 "C; 8,30 min at 121 "C.
decreased to 40 AU ml-l after only 30 rnin at 100 "C ( Fig. 1) . When stored for 4 weeks at -20 "C, mesentericin Y105 kept its activity (data not shown). Long term storage at -20 "C indicated that bacteriocin was active for at least 6 months. At 4 "C, the bacteriocin had to be stabilized by preliminary heat treatment and low pH, whereas storage at room temperature was not appropriate, because rapid loss of activity occurred. These experiments demonstrated that the inhibitory activity was due to a proteinaceous molecule sensitive to proteases but exhibiting excellent heat stability and stability under acidic conditions. The heat tolerance suggested the mesentericin to be a low-molecular-mass bac te rioc in.
Estimation of molecular mass
SDS-PAGE was used to estimate the molecular mass of mesentericin Y 105. Silver stain and other dyes such as Coomassie blue R250 are poorly bound by mesentericin Y105. Therefore, direct detection via its activity in SDSpolyacrylamide gels appeared to be a better method provided it was not affected by the detergent. Fig. 2 shows that the apparent molecular mass could be estimated in this way to be 2.5-3.0 kDa. Moreover, since its biological activity remained after SDS-PAGE, it seems that this protein is either refractory to detergent action, or able to renature during the assay. * Protein concentration (mg m1-I) was estimated by AZ2,,/1 1 (Scopes, 1988) .
t The activity of the sample arising from affinity chromatography was reassessed at the same time as the ultrafiltered fraction.
peptides. The crude supernatant fraction was loaded onto an affinity chromatography column. This first step greatly increased the specific activity ( x 779) because the column retained only a very small amount of supernatant proteins, among which was the mesentericin Y105. However, after this initial step, the specific activity of the bacteriocin fraction dramatically dropped by approx. 80% when left for 8 h at 4°C. The sample was concentrated by ultrafiltration and then dialysed to lower its salt content. Both ultrafiltration and dialysis led to a loss of activity compared to the preceding purification step, as indicated in Table 2 . In spite of this decline, ultrafiltration through a membrane with a cut-off of 5 kDa allowed the removal of small peptides, whereas the bacteriocin behaved as a higher molecular mass peptide, possibly due to multimerization or association with macromolecules. The final step was reverse-phase HPLC. The bacteriocin was retained under initial conditions and then eluted with 32% (v/v) acetonitrile under a major peak (Fig. 3) . Its protein content was estimated by UV absorption at 220nm. According to UV spectrum analysis (205-230nm) of the peak using the Focus program (Spectra-Physics), the bacteriocin was considered purified to homogeneity. Part of the pure mesentericin Y 105 sample was used for trypsin digestion, followed by HPLC separation of 4 peptides (data not shown).
Primary sequence
The amino-terminal analysis of the complete protein gave the amino acid sequence appearing in Fig. 4 . After 36 amino acid residues, no other phenylthiohydantoinderivatized residues became detectable after 10 additional cycles. Morever, this sequence was confirmed by the following tryptic peptides: mixture ending with Lys or Arg correspond to expected cleavage sites by trypsin, the second peptide with a carboxy-terminal Gly results from a non-specific cut and the third is obviously the carboxy-terminal part of mesentericin Y 105. Its calculated molecular mass on the basis of amino acid sequence is 3666.6 Da.
Discussion
Mesentericin Y 105 is the first bacteriocin, inhibiting growth of Listeria monocytogenes, which is produced by a Leuconostoc mesenteroides ssp. mesenteroides, isolated from goat's milk. recently described a bacteriocin, leucocin A-UAL 187, produced by a Leuconostoc gelidum isolated from vacuum-packaged meat, that shows a strong similarity with mesentericin Y 105. It is noticeable that the leucocin-A-UAL-187-producing strain was originally identified as a Leuconostoc mesenteroides ssp. mesenteroides and later it was classified as a Leuconostoc gelidum is not yet known. The general properties of mesentericin are characteristic of the particular family of low-molecular-mass bacteriocins. It remains active at low pH and is unaffected by heat treatment, similar to most of these peptides (Hasting & Stiles, 1991) . We observed that heat pre-treatment of crude extract seems to stabilize the activity. This may be due to the denaturation of proteases which could also be produced by the Leuconostoc mesenteroides. As described by Merill (1 990), some proteins are difficult to stain for unknown reasons. Therefore, detection was achieved by a direct activity assay as described by Bhunia et al. (1987) after Tricine-SDS-PAGE (Shagger & Von Jagow, 1987). According to this assay, mesentericin Y105 has a molecular mass of 2.5-3.0 kDa. Like some bacteriocins (Joerger & Klaenhammer, 1986; Mortvedt et al. 1991) , mesentericin Y105 seems to aggregate with other substances under non-denaturing conditions or simply associates into polymer forms. Whether this phenomenon affects its biological activity is not yet known.
Although production of this bacteriocin was consistently higher ( x 16) in MRS medium, the specific activity of crude extracts was lower than in the defined medium. As a consequence, the latter was chosen to simplify the purification process. For the first step, the 'Mimetic Blue 1' was first selected from 10 different dyes from the Piksi System (ACL, Cambridge, UK). It was later substituted by a similar dye, 'Blue agarose', which displayed a higher specificity for the bacteriocin. The use of a defined medium linked to dye-affinity-chromatography is the main feature of this process leading to pure mesentericin in a simple manner. By comparison, leucocin A-UAL 187 purification was conducted by an ammonium sulphate precipitation followed by three steps of chromatography (Hastings et al., 1991) . Thus, the scheme described here opens up the possibility for scaling-up mesentericin preparation in order to use this bacteriocin in structural studies or even as a food preservative. However, the problem of the stability of the activity after the first chromatography step has to be addressed. Different protease inhibitors were tested without delaying the loss of activity (data not shown), so it is unlikely to be due to bacteriocin proteolysis. Inactivation of Purification of anti-Listeria mesentericin YIOS 273 1 mesentericin Y 105 could also result from a specific effect on the catalytic site, such as loss of cofactors or covalent modifications. Moreover, early studies described a quick loss of activity with very dilute enzymes.
Finally, reverse-phase HPLC yields pure bacteriocin. This sample and its tryptic fragments were directly used for protein sequencing leading to the total sequence of mesentericin Y 105. Comparison with the primary structure of other proteins (EMBL data bank) indicates that mesentericin Y 105 sequence (36aa) is close to that of leucocin A-UAL 187 (Hastings et al., 1991) which contains an extra tryptophan residue at the carboxyterminus and displays only two differences in the sequence, a phenylalanine and a valine in place of alanine-22 and isoleucine-26, respectively.
Finally, it will be very interesting to investigate the mesentericin Y 105 target selection and mode of action. It is not yet known whether a specific membrane receptor is involved as described for colicins (Pattus et al., 1990) and recently suggested by Van Belkum et al. (1991) for lactococcin A produced by a Lactococcus lactis, or, like some lantibiotics, targeting is driven by a particular phospholipid composition of cytoplasmic membranes (Kordel et al., 1988; Gao et al., 1991) . Flow cytometry and oxymetry analysis (unpublished results) indicate that mesentericin Y 105 decreases membrane potential and oxygen consumption of Listeria cells. Studies are in progress to understand the mode of action of these bacteriocins at the molecular level.
